{"name":"Trishula Therapeutics, Inc.","slug":"trishula-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Trishula Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for cancer. The company's lead candidate, TTX-030, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBFNTBOXzlKQ0dDdmxwS1prYVdpaFhCRVo3Q19ETmxOUVdCZ09uSHdSUXZkYnlzUzhVeGp2NW56UldvV2luMmxfWjFzT21nUU1lVzlsUzQxdUlac0VCRmdNdnFHYWI?oc=5","date":"2025-08-31","type":"pipeline","source":"Oncodaily","summary":"JCO on a Jamaican Beach: The Journey of Joyson Karakunnel - Oncodaily","headline":"JCO on a Jamaican Beach: The Journey of Joyson Karakunnel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1JRHVnc2NhdUFQZVo2OXA1VkhwbVpWWFJldG1UNXVsREZoYmJHaEFBVy10TkpScEhEVEVxQmlicjVZVGlNYXVtRnpRdWxYUVhtR01tVkNEbWxoQzZDZUd6c2dCSl9oaDBGN2RacHNLZTMxWGtPOENaSQ?oc=5","date":"2024-09-17","type":"trial","source":"Clinical Trials Arena","summary":"Trishula Therapeutics reports results from Phase I trial of pancreatic cancer drug - Clinical Trials Arena","headline":"Trishula Therapeutics reports results from Phase I trial of pancreatic cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPRkVDdFVRc0Q5alVXb2tWbFVfc0g4TDRXUldOeV96ZmhoVGs5c0dhY3FfOHpDOGJnWTRBSzNUTV9UcVpVUlU5eXYweG5vLTZQMVJqbnlCOFpndHBvUnlHN1NMNXJ5NkdZd1lIQVlSbEVPemlXRGVPWEE2bjJnbmgzMHhTZEotNi1MSVM5MWVTRkNyZWxDc0tBc3RqeFdmTnBhWG5aTXIzYWZVeld5eUV2dThETF82R1Q5WHZVSHVoZ1JsNHAtT2dvdzhWQkR6MnN1cjVGelVMUXJNam5EUHAwc21rLUhYbm5reFJoVk0zSVdic01vOGJDVF9hMkhXSXB2RzdHa01aOHZWbzN5WVJ6bEVTNA?oc=5","date":"2024-09-16","type":"trial","source":"PR Newswire","summary":"Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients - PR Newswire","headline":"Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPLVhDbnVkSGZiWmtNczhuekE1UkVCcWNoRFBreXUtU0Q1RnVPSEZvTEM1ZGRwckNnVmlwM2dkN29ibFFBdHFRZHVLa1hRVEYtR3JPN1lVRlhhTXlVekhUUnFOLVJmcGpiVEZGckU3QW9BX084T0V0Tm00a25QeHFoMFpkU0ZGdGZucWdBZC1QSnNQUm5MNV9mSThGTUg3UzU3Y0ZzM21fR05iRS1SOGNSdG5hS2FWeTdLUE1FXzVlQ1dkT3pFdk5XZWlYSmpCbm1naVVjS3NxcWYyUENBdkVfR3BsNm5DZUdpWm1WUmExZnkzWV9abG4xX05YdjRuRUlpdTA1S1QyOEJGcC1OaHBKMUFKUWc?oc=5","date":"2023-11-09","type":"trial","source":"PR Newswire","summary":"Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients - PR Newswire","headline":"Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Can","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1Mb0txMXlPcFlHUWV5dFEyUEJVWW9QdWc0WG1vcUdfVWM5QWZuLUh4ZGhNdDEtcDFCT05RNHhaNTNuVjhGSmQ3QmV1cVZITU1aVE5R?oc=5","date":"2023-07-24","type":"deal","source":"Lightspeed Venture Partners","summary":"Dr. Shelley Chu - Lightspeed Venture Partners","headline":"Dr. Shelley Chu","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}